BioPharma Dive December 22, 2025
Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, an “off the shelf” cell therapy showed promise.
Today, a brief rundown of news from The Centers for Medicare and Medicaid Services and Shionogi, as well as updates from AstraZeneca, CRISPR Therapeutics and Boehringer Ingelheim that you may have missed.
The Trump administration has proposed a pair of new Medicare pilot programs meant to lower U.S. drug prices by tying rebates and costs in the U.S. to what’s paid in comparable countries. Called “Globe” and “Guard,” both payment models would force drug companies to offer rebates that cover the difference in prices paid in the U.S. and a group of comparable...
Today's Sponsors
Today's Sponsor